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influence reimbursement at national/regional level were interviewed. Results: 
Interviewed EU5 payers emphasize that there are high administrative costs involved 
with providing opioid substitution products to addicted patients, especially for metha-
done, which generally requires daily clinic visits to allow patients to receive their 
medication under direct supervision. A substitution therapy requiring less-frequent 
clinic visits would decrease administrative costs and could be preferred as long as 
efficacy parameters relative to standard-of-care are maintained. Similarly, surveyed 
EU5 physicians indicate that potential for abuse or diversion and patient compliance 
are major considerations for prescribing a new therapy (15% [Spain] to 24% [France] 
and 28% [UK] and 52% [Spain] of respondents cite these factors, respectively, as a 
top three consideration). The former could be decreased and the latter increased if 
therapies were dosed less frequently. A long-acting buprenorphine injection, such 
as Camurus/Braeburn Pharmaceuticals’ CAM-2038, could, therefore, appeal to both 
payers and prescribers. Indeed, 86-96% of surveyed physicians are willing to prescribe 
CAM-2038 if it establishes a similar efficacy, safety, and tolerability profile to exist-
ing buprenorphine products in clinical trials. ConClusions: The opioid addiction 
market is dominated by generic products. However, while payers and prescribers are 
constrained by tight healthcare budgets, our primary research indicates that new 
brands such as long-acting depot CAM-2038 could gain traction via powerful market-
ing that focuses on their ability to reduce potential for abuse/diversion and increase 
compliance, provided existing efficacy and safety standards are maintained.
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objeCtives: Nalmefene (Lundbeck’s Selincro) is the only marketed drug that 
aims to reduce alcohol consumption rather than maintain abstinence in alcohol-
dependent patients. By examining reimbursement and uptake of nalmefene in the 
EU5, we explore market access challenges for the novel treatment pathway this 
drug represents. Methods: In February 2015, 253 psychiatrists in France, Germany, 
Italy, Spain, and the UK were surveyed regarding their prescribing of nalmefene. In 
addition, 15 EU5 payers involved in determining and regulating access to alcohol 
addiction pharmaceuticals were interviewed. Results: On average, 10% (UK) to 
30% (France) of surveyed physicians’ drug-treated alcohol-addicted patients receive 
nalmefene. The most commonly cited reasons for not prescribing nalmefene are 
unfamiliarity with the drug (especially in the UK), a belief that the treatment goal 
should be abstinence, and preference for another pharmacotherapy. Furthermore, 
20% of all surveyed EU5 psychiatrists cite maintaining abstinence/reducing relapse 
as the greatest unmet need in the pharmacological treatment of alcohol addiction, 
while 18% (UK) to 38% (France) identify efficacy for maintaining complete abstinence 
from alcohol after withdrawal and detoxification as their key driver for prescribing 
a new therapy. Interviewed payers similarly consider nalmefene’s goal of reducing 
alcohol consumption rather than maintaining abstinence to be a reimbursement 
challenge, and one that, alongside perceived modest efficacy, has contributed to 
suboptimal HTA ratings in France and Germany, and to total lack of reimbursement 
in Italy. ConClusions: Perception of abstinence as the main aim of treatment 
for alcohol addiction is a considerable market access hurdle for nalmefene and 
emerging alcohol consumption-reducing agents. Robust superiority over compara-
tors, persuasive marketing that illustrates the benefits of alcohol reduction versus 
abstinence, and effective targeting of national, regional and local stakeholders are 
essential to encourage payers to think beyond the price tag, and to maximize famili-
arity with and use of this novel treatment pathway among prescribers.
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objeCtives: To assess the differences in the utilization of drugs indicated for AD 
treatment across different geographic areas in Turkey and to identify the factors 
that may influence possible disparity in the usage. Methods: Summary data for 
all 81 cities in Turkey have been collected. The data include IMS sales (standard 
unit sales data of all products indicated for AD -memantin, rivastigmin, donepezil, 
galantamin), demographic (age distribution, education level, population density 
etc.), health policy (number of family physicians and specialists, hospital beds, nurs-
ing houses, average hospital admission rate) and affordability data (social security 
coverage rate). We calculated “utilization score” for all cities, dividing the number 
of standard units sold by the number of subjects who are assumed to have AD. A 
composite “indicator score” was calculated for all cities, summing the weighted val-
ues of all indicators. The relationship of the indicators and the composite indicator 
scores with “utilization score” were analyzed by means of Pearson and Spearman 
correlation analysis as needed. Then, a multivariate regression model was built to 
determine the degree of impact of each indicator. Results: There were significant 
differences in the relative utilization of AD treatments among cities and regions. 
Generally industrialized and larger cities had higher utilization than smaller and/
or less-developed cities by means of infrastructure. It is seen from the multivariate 
regression model that, utilization Index increases when SGK coverage rate and 
population density increase and when household size decrease. ConClusions: 
Geographical disparities in the usage are initially assumed to be related to scarci-
ties in healthcare infrastructure and regional socio-economic factors. However, it is 
seen that healthcare infrastructure is less influential on utilization disparity, which 
has found to be highly driven by socio-economics factors including affordability, 
population density (disperse residence) and household size (indirect indicator for 
socio-economy and family member to provide caregiver service in Turkish culture)
patients and one of caregivers. ConClusions: Most study abstracts reporting 
on the humanistic burden in dementia in 2014 did not specify use of a dementia-
specific instrument. Only 25% of studies assessed burden on caregivers, and utility 
values were rarely reported.
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objeCtives: To evaluate the association between caregiver’s reported attention-
deficit/hyperactivity disorder (ADHD) medication satisfaction (MS) and child and 
caregiver socio-demographics; ADHD severity; comorbidities; medication attributes; 
treatment classes. Methods: CAPPA is a cross-sectional online survey of caregivers 
of children (6–17 years) with ADHD receiving pharmacological treatment for ADHD at 
survey completion (2012–2013) in 10 European countries. ADHD Rating Scale Version 
IV (ADHD-RS-IV) total score during treatment interruption (off medication) was used 
as a proxy for baseline severity. Caregivers were asked to rate satisfaction with medi-
cation attributes (Convenience: administration frequency, tablet size; Effectiveness: 
duration of action, time to onset, symptom control; Safety: side effects, abuse/mis-
use potential, dependence/addiction potential) on a 7-point scale ranging from ‘very 
satisfied’ to ‘very dissatisfied’. Children’s comorbidities at baseline/treatment classes 
were also reported by caregivers. Significant factors (p< 0.01) using bivariate and cor-
relation analyses are reported. Results: Among 3688 respondents, 2853 (77%) whose 
child was using ADHD medication at survey completion were evaluated. Children’s 
mean (SD) age was 11.4 (3.1) years, 81% were male; 67% of caregivers were female. 
MS was rated as: very satisfied (20%), satisfied (39%), moderately satisfied (29%), and 
combined neither satisfied nor dissatisfied, moderately dissatisfied, dissatisfied or 
very dissatisfied (12%). Better MS was reported with lower ADHD severity and fewer 
comorbidities. Comorbidities significantly associated with lower MS were anxiety, 
conduct disorder, aggression and oppositional defiant disorder. Medication attributes 
with strongest correlation to MS were symptom control (r= 0.6), duration of action 
(0.5) and time to onset (0.4). Significantly higher MS was associated with caregivers 
who were married, female, employed or a parent with ADHD. MS varied by coun-
try. ConClusions: Lower ADHD severity and fewer comorbidities were associated 
with higher MS. Effectiveness attributes were of highest priority to caregivers and 
MS differed by caregiver characteristics. These factors should be considered when 
making a treatment plan.
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objeCtives: Mental Health Disorders impair occupational performance and 
lead to handicap and economic deprivation. The current contribution quantifies 
the degree of these problems among two representative samples of the German 
and the UK population. Methods: Two representative samples (n= 3,571) of the 
adult population (20-65 years) in Germany and UK were surveyed in 2012 with 
a questionnaire containing information about occupational status, job related 
handicaps, economic and demographic information. From a survey five years 
earlier (2007) information for the same persons about possible mental health 
disorders and their treatment were available. Longitudinal regression analysis 
estimates the impact of mental status on occupational disability and financial 
deprivation Results: In the initial survey 18.5% of the sample suffered from 
depression and 7.0% from anxiety/ phobia. 53.8% of the depressive individuals 
and 56.8% of the individuals suffering from anxiety or phobia were treated by 
General Practitioners or Specialists. Five years later unemployment due to men-
tal health reasons was reported by 57.2% of the persons with treated mental 
health disorders but only by 19.9% of the group with no mental health disorders. 
Individuals with mental disorders needed – among other handicaps - more often 
breaks at work than persons with no disorders (33.3% vs. 8.5%) or could no longer 
perform all elements of their jobs (28.9% vs. 6.9%). Occupational handicap resulted 
in economic deprivation: 28.0% of the treated mental health group reported a 
monthly net income of less than 800GP compared to 13.2% of the group with no 
mental health disorders. ConClusions: Mental Health Disorders have consider-
able impacts on occupational performance, participation in work life and on the 
financial economic situation. Individuals who are under treatment suffer more 
often from these handicaps than untreated - presumably because of their more 
severe disease status.
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objeCtives: Standard-of-care for opioid addiction is substitution therapy with 
methadone, buprenorphine, or buprenorphine/naloxone. As EU5 healthcare budgets 
tighten, this study explored how emerging brands may gain a foothold in this increas-
ingly generic market, as payers and prescribers balance clinical need with limited 
funds. Methods: In February 2015, 253 EU5 psychiatrists were surveyed regarding 
their prescribing for opioid addiction. In addition, 15 payers/payer-advising KOLs who 
